High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

被引：34

作者：

Karuturi, Meghan ^{[1
]}

Hosing, Chitra ^{[1
]}

Fanale, Michelle ^{[2
]}

Medeiros, L. Jeffrey ^{[3
]}

Alousi, Amin M. ^{[1
]}

de Lima, Marcos J. ^{[1
]}

Qazilbash, Muzaffar H. ^{[1
]}

Kebriaei, Partow ^{[1
]}

Younes, Anas ^{[2
]}

Khouri, Issa ^{[1
]}

Andersson, Borje S. ^{[1
]}

Champlin, Richard ^{[1
]}

Anderlini, Paolo ^{[1
]}

Popat, Uday ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2013年 / 19卷 / 06期

关键词：

Hodgkin Lymphoma; Autologous stem cell transplantation; Nodular lymphocyte predominant Hodgkin lymphoma; Relapse; Chemosensitive; STUDY-GROUP GHSG; LONG-TERM; MARROW-TRANSPLANTATION; RITUXIMAB; PHASE-2; DISEASE; TRIAL;

D O I：

10.1016/j.bbmt.2013.03.008

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL. (C) 2013 American Society for Blood and Marrow Transplantation.

引用

页码：991 / 994

页数：4

共 13 条

[1]

Bartlett Nancy L, 2005, Hematology Am Soc Hematol Educ Program, P245

[2] Nodular, Lymphocyte-Predominant Hodgkin Lymphoma A Long-Term Study and Analysis of Transformation to Diffuse Large B-Cell Lymphoma in a Cohort of 164 Patients From the Adult Lymphoma Study Group [J].

Biasoli, Irene ;

Stamatoullas, Aspasia ;

Meignin, Veronique ;

Delmer, Alain ;

Reman, Oumedaly ;

Morschhauser, Franck ;

Coiffier, Bertrand ;

Bosly, Andre ;

Divine, Marine ;

Brice, Pauline .

CANCER, 2010, 116 (03) :631-639

[3]

Bierman P, 2006, BLOOD, V108, p1a

[4] The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications [J].

Campo, Elias ;

Swerdlow, Steven H. ;

Harris, Nancy L. ;

Pileri, Stefano ;

Stein, Harald ;

Jaffe, Elaine S. .

BLOOD, 2011, 117 (19) :5019-5032

[5] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[6]

Crump Michael, 2008, Hematology Am Soc Hematol Educ Program, P326, DOI 10.1182/asheducation-2008.1.326

[7] Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group [J].

Eichenauer, Dennis A. ;

Fuchs, Michael ;

Pluetschow, Annette ;

Klimm, Beate ;

Halbsguth, Teresa ;

Boell, Boris ;

Von Tresckow, Bastian ;

Nogova, Lucia ;

Borchmann, Peter ;

Engert, Andreas .

BLOOD, 2011, 118 (16) :4363-4365

[8] Lymphocyte-predominant Hodgkin lymphoma-clinical features and treatment outcomes from a 30-year experience [J].

Jackson, C. ;

Sirohi, B. ;

Cunningham, D. ;

Horwich, A. ;

Thomas, K. ;

Wotherspoon, A. .

ANNALS OF ONCOLOGY, 2010, 21 (10) :2061-2068

[9] Nodular Lymphocyte Predominant Hodgkin Lymphoma [J].

Lee, Alfred Ian ;

LaCasce, Ann S. .

ONCOLOGIST, 2009, 14 (07) :739-751

[10] DOSE INTENSIFICATION WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN RELAPSED AND RESISTANT HODGKINS-DISEASE - RESULTS OF A BNLI RANDOMIZED TRIAL [J].

LINCH, DC ;

WINFIELD, D ;

GOLDSTONE, AH ;

MOIR, D ;

HANCOCK, B ;

MCMILLAN, A ;

CHOPRA, R ;

MILLIGAN, D ;

HUDSON, GV .

LANCET, 1993, 341 (8852) :1051-1054

← 1 2 →